Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.65 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931623 | 0.91 | PIK3CA (0.63) | PIK3CAPIK3C3PIK3CBPIK3CDPIK3R1 | |
| SCHEMBL931532 | 0.91 | PIK3CA (0.72) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL931536 | 0.91 | PIK3CA (0.75) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL931535 | 0.91 | PIK3CA (0.75) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL931572 | 0.91 | PIK3CA (0.75) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL11909889 | 0.90 | PIK3CA (0.66) | PIK3CAPIK3C3PIK3CBPIK3CDPIK3R1 | |
| SCHEMBL932348 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL930780 | 0.85 | PIK3CA (0.63) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL932006 | 0.83 | PIK3CA (0.73) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG | |
| SCHEMBL932007 | 0.83 | PIK3CA (0.73) | PIK3CAPIK3C3PIK3CBPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | claimed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2448940-B1 | 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| EP-2448940-B1 | 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2448940-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | ALK, HAX1, HCLS1 | PIK3CA 3059/4885PIK3C3 3977/4885PIK3CB 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.